Skip to content
FDAMedicines

Baxter Issues Voluntary Nationwide Recall of Cefazolin in Dextrose Injection, USP, 2G / 100ml(20mg /ml) Single-Dose Infusion Bag in 100ml Due to Particulate Matter Found in Solution

FDA recall n-baxter-issues-voluntary-nationwide-recall-cefazolin-dextrose-injection-usp-2g-10 ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Particulate matter (cardboard) found in the solution.
Text from FDA, unedited.

The recalled product

Codes in the record. Click one to copy it.

July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling Lot LD175708, Exp 14-Feb 2027 of Cefazolin in Dextrose Injection due to a report of particulate matter found in the solution identified as cardboard.Risk Statement: The use of the defective product has a
Text from FDA, unedited.

Company announcement, as FDA publishes it

July 24, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling Lot LD175708, Exp 14-Feb 2027 of Cefazolin in Dextrose Injection due to a report of particulate matter found in the solution identified as cardboard.

Risk Statement: The use of the defective product has a reasonable probability of causing pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or phlebitis (inflammation of the walls of veins, which may lead to clotting). Systemically, foreign particles infused intravenously can cause systemic activation of the immune system, organ dysfunction, and hemolysis (breakdown of blood cells). To date, Baxter has not received any reports of adverse events related to this issue.

Affected Product: This product is used intravenously to treat bacterial infections or prevent them during surgery

The affected lots can be identified by locating the lot number and expiration date on the front of the product package and the label attached to the carton, as shown in the images below.

The impacted product was distributed from 3/25/2025 to 6/30/2025 in the United States.

Customers should immediately discontinue use of and return all affected units in accordance with their facility’s process. Baxter is contacting customers with instructions on how to identify and return the impacted product.

For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online: www.fda.gov/medwatch/report.htm

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

The United States Food and Drug Administration (FDA) has been notified of this action.

Text from FDA (the company’s words), unedited.
  • Cefazolin in Dextrose Injection, USP, 2g / 100mL (20mg / mL) Single-Dose Infusion Bag in 100mL GALAXY Plastic Container, Frozen Premix

    Lot or code
    Product Code: 2G3508; Lot Number: LD175708; Expiration Date: 14-Feb-2027; NDC Number: 0338-3508-41

Source

Issued by
U.S. Food and Drug Administration
Firm
Baxter International Inc.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Baxter International Inc., Month: July 2026, Week 2026-W30. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Particulate matter (cardboard) found in the solution.”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on July 24, 2026.

Other notices of Baxter International Inc.